Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it-Reference-Cited by-同舟云学术

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Published:2020-12-14 Issue:2 Volume:178 Page:239-261
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Wang Yuanyuan¹,Chen Jiyuan¹,Wu Zhengjie²,Ding Weihong³,Gao Shen²,Gao Yuan¹^ORCID,Xu Chuanliang²

Affiliation:

1. Department of Clinical Pharmacy and Pharmaceutical Management, School of Pharmacy Fudan University Shanghai China

2. Department of Urology Changhai Hospital, Second Military Medical University Shanghai China

3. Department of Urology Huashan Hospital, Fudan University Shanghai China

Funder

Shanghai Municipal Education Commission

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15300

Reference173 articles.

1. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor

2. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors

3. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets

4. Alizadeh M. Sazegar H. Zia N. Farsani F. M.(2018).Study of the effects of rs137852595 single‐nucleotide polymorphism on drug resistance of androgen receptor against Enzalutamide treatments in patients with prostate. Retrieved fromhttps://www.researchgate.net/publication/332544381

5. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway;Neoplasia;2024-11

2. Potential drug targets for prostate cancer ： A mendelian randomization study and application for target-derived drug design;2024-09-02

3. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer;Endocrinology;2024-08-27

4. Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells;Cancers;2024-08-24

5. Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators;Cell Death & Disease;2024-08-03